femasys logo 2.jpg
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
10 oct. 2024 08h30 HE | Femasys Inc.
ATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
femasys logo 2.jpg
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
08 oct. 2024 08h30 HE | Femasys Inc.
ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
femasys logo 2.jpg
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
02 oct. 2024 08h30 HE | Femasys Inc.
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
femasys logo 2.jpg
Femasys Announces Infertility Clinic Customers from Coast to Coast
18 sept. 2024 08h30 HE | Femasys Inc.
ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
femasys logo 2.jpg
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
11 sept. 2024 08h30 HE | Femasys Inc.
ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
femasys logo 2.jpg
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
09 sept. 2024 08h30 HE | Femasys Inc.
ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
femasys logo 2.jpg
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
05 sept. 2024 08h30 HE | Femasys Inc.
ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
femasys logo 2.jpg
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 08h30 HE | Femasys Inc.
ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
femasys logo 2.jpg
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
29 août 2024 08h30 HE | Femasys Inc.
ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
femasys logo 2.jpg
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
27 août 2024 08h30 HE | Femasys Inc.
ATLANTA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...